Canada-based YM BioSciences, a cancer product development company, has entered into an agreement to acquire Eximias Pharmaceutical, headquartered in Pennsylvania. YM will expand the latter company's cancer drug research and development program, the company reported.
The acquisition will allow YM to expand its capabilities for the development and commercialization of the products currently in clinical development and to establish a presence in the U.S., the company said.
Eximias focuses on the development and commercialization of products for the treatment of cancer, cancer-related and acute-care disorders. The company's primary products are thymitaq (nolatrexed) and orataq (an oral form of nolatrexed), both cancer therapeutics.